Results 131 to 140 of about 128,993 (222)
Hideaki Yoshimura, Masaaki Hotta, Takahisa Nakanishi, Shinya Fujita, Aya Nakaya, Atsushi Satake, Tomoki Ito, Kazuyoshi Ishii, Shosaku Nomura First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka ...
Ito T +8 more
core
A biosimilar medicine is a successor to a reference ('originator'/'original-brand') biologic medicine brought to market once the patent and exclusive marketing rights for the reference have expired.
Poetzl, Johann +9 more
core +1 more source
Biosimilar insulin analogues are increasing market access for diabetic patients globally. Scientific establishment of biosimilarity is cornerstone of this key change in the medical landscape.
Nikhil S. Ghade +4 more
doaj +1 more source
As of 31 December, 2023, 31 observational studies have been published, including a total of 6081 patients who underwent a switch from one biosimilar to another biosimilar of the same reference biologic.
Cohen, Hillel, Bodenmueller, Wolfram
core +1 more source
Ian N Foltz,1 Kevin Gaida,2 Helen Y Wong,1 Michael Ng,1 Marijana Busch,1 Jennifer L Liu3 1Amgen Research, Department of Therapeutic Discovery, Amgen Inc., Burnaby, BC, V5A1V7, Canada; 2Research and Development, Amgen Inc., Thousand Oaks, CA, 91320, USA ...
Foltz IN +5 more
doaj
The Impact of Biosimilar Launch on Molecule Price and Pharmaceutical Expense: The Case of the Insulin Glargine in Italy [PDF]
A Tettamanti, L Cioni, C Tucci
openaire +1 more source
Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review [PDF]
Grace E Fox,1 Mark Bernauer,1 Jennifer M Stephens,1 Bianca Jackson,1 Joshua A Roth,2 Ahmed Shelbaya2,3 1Strategic Market Access, OPEN Health, Bethesda, MD, USA; 2Global Access and Value, Pfizer Inc., New York, NY, USA; 3Department of Epidemiology ...
Stephens JM +5 more
core
Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data
Juan Pedro López-Siguero,1 Roland Pfäffle,2 Philippe Chanson,3 Mieczyslaw Szalecki,4,5 Nadja Höbel,6 Markus Zabransky6 1Servicio de Endocrinología Pediátrica, Hospital Materno-Infantil, Hospital Regional Universitario de M&
Zabransky M +5 more
core
Purpose: To understand the early experience of ranibizumab biosimilar (FYB 201) that has been approved in the United Kingdom (Ongavia, Teva Pharmaceuticals, Tel Aviv Israel), United States (Cimerli, Sandoz Inc, Princeton, NJ, USA) and Europe (Ranivisio ...
Mansour, Hana +17 more
core +1 more source
Key Regulatory Considerations for the Development of Biosimilar Pharmaceutical Products
openaire +1 more source

